Navigation Links
ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe
Date:2/27/2008

SALT LAKE CITY, Feb. 27 /PRNewswire/ -- ZARS Pharma, Inc. announced today that Rapydan(R) (70 mg lidocaine/70 mg tetracaine medicated plaster) has now received marketing authorization in Sweden, the United Kingdom, the Netherlands, France, Spain, Austria, the Czech Republic, Greece, Ireland, Norway and Portugal following the completion of the European Mutual Recognition Procedure. ZARS Pharma has licensed the European sales and marketing rights of Rapydan to EUSA Pharma, Inc. Rapydan received marketing authorization in Sweden in January 2007 and was launched in May 2007. EUSA Pharma began launching Rapydan in other European Union countries in early 2008.

Rapydan is a topical local anesthetic patch approved for use on normal and intact skin to provide surface anesthesia of the skin in connection with needle punctures, in children from 3 years and above, and needle punctures and superficial surgical procedures in adults. Rapydan resembles a small adhesive bandage in appearance and is similar in its ease of application. The patch is applied to the skin for 30 minutes before painful medical procedures. Rapydan is the first product approved in Europe using the patented Controlled Heat-Assisted Drug Delivery or CHADD(R) technology developed by ZARS Pharma.

Rapydan is marketed as Synera(R) (lidocaine 70 mg and tetracaine 70 mg) in the United States and was approved by the U.S. Food and Drug Administration in 2005.

Robert Lippert, President and Chief Executive of ZARS Pharma stated, "We are pleased to announce the approval of Rapydan in a number of European Union countries with a uniquely positioned commercial partner. Rapydan is the first anesthetic patch innovation to be approved in over a decade that works faster than the current standard of care and will soon become a best-in-class therapy for patients undergoing painful needle procedures."

About Rapydan

Rapydan is comprised of a thin layer of a patented local anesthetic formula
'/>"/>

SOURCE ZARS Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... GMO corn cases filed across the United States, ... of being consolidated in a Kansas federal court for pretrial ... 162 Corn Litigation, MDL No. 2591 in the U.S. District ... Syngenta GMO corn multidistrict litigation (MDL) has been handed over ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Nventa Biopharmaceuticals,Corporation (TSX: NVN) today announced financial results for ... and highlighted several,recent product developments and corporate milestones., ... Recent product and corporate highlights:, o ... it will initiate a ...
... Risks of Progression of,Vertebral Fracture in US-Caucasian Women, ... (Amex: ILI ), announced today that Nazneen ... Development, will present new research,findings on the genetics ... the,American Society of Human Genetics, which takes place ...
... LLC, a privately-held,biopharmaceutical company focused on developing novel ... Sindbis viral vector, announced today,that it has appointed ... immediately, to lead the company,s next phase of ... Stonebanks will serve on Cynvec,s Board,of Directors., ...
Cached Biology Technology:Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 2Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 3Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 4Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 5Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 6Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 7Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics 2Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics 3Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 2Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 3
(Date:1/22/2015)... Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of ... of its new website design. "When we launched ... says Peter O,Neill , founder and CEO of FindBiometrics. ... needs involvement from the key players on a very broad ...
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... red wormlike insects that nibble on the plant's leaves ... larvae that survive eventually evolve methods to overcome plant ... trying to thwart the insect have identified Hessian fly ... itself from the munching larvae. The researchers report their ...
... target organs or cell types, you need a good ... the target in question could do the trick. , ... tiny capsules require preorganized structures or "molds" to shape ... synthetic or purification procedure. Korean researchers led by Kimoon ...
... have discovered how cells fine-tune their oxygen use to make ... Too little oxygen threatens life by compromising mitochondria that power ... by replacing one protein with an energy-efficient substitute that "is ... begins to run out of gas," says Gregg Semenza, M.D., ...
Cached Biology News:Scientists find genes involved in the battle between Hessian flies and wheat 2Scientists find genes involved in the battle between Hessian flies and wheat 3Navigable nanotransport 2Need oxygen? Cells know how to spend and save 2
Request Info...
... Vector NTI Advance ... complete and highly integrated ... analysis and molecular biology ... graphics readily available for ...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Biology Products: